OMIX

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer-cohort A

OMIX001548

1Summary
Title Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer-cohort A
Description Previous small size studies reported BRAF mutated NSCLC patients have comparable sensitivity to immune checkpoint inhibitors (ICIs). However, how BRAF mutation affects the tumor immune microenvironment (TIME) of NSCLC is unknown. We performed Nanostring-panel RNA sequencing to evaluate TIME in 57 BRAF mutated and wild-type (WT) NSCLC specimens (cohort A). The efficacy of ICI monotherapy or combined therapies was determined in 417 patients with WT and BRAF mutated NSCLC (cohort B).
Organism Homo sapiens
Data Type Biomarker Data
Data Accessibility Open-access
BioProject PRJCA011037
Release Date 2022-08-09
Submitter Hui Li (11118029@zju.edu.cn)
Organization Zhejiang Cancer Hospital
Submission Date 2022-08-07
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download Times Download
OMIX001548-01 NanoString gene expression data for cohort A 57 Biomarker Data 2.9 MB zip 0

View All Released Data of OMIX